Trial of Vitamin D Supplements to Raise Calcidiol Levels of Pregnant Women in Mongolia
NCT ID: NCT02395081
Last Updated: 2021-03-23
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
360 participants
INTERVENTIONAL
2015-02-28
2016-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Vitamin D Supplementation and Pregnancy Outcomes
NCT03308487
Controlled Trial of Prenatal Vitamin D3 Supplementation to Prevent Vitamin D Deficiency in Mothers and Their Infants
NCT00610688
Antenatal Vitamin D3 Supplementation in Bangladesh: Randomized Controlled Trial
NCT01126528
Antenatal Vitamin D3 Dose-finding and Safety Study
NCT00938600
Effects of Vitamin D Supplementation During Pregnancy on Clinical Outcomes and Immune Function
NCT01417351
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Observational studies in the U.S. have linked low 25(OH)D levels in women to a higher risk of preeclampsia. Mongolians also report levels of preeclampsia that are 3 times higher than those in the U.S (official reports cite 15%, though this may include gestational hypertension).
Given the widespread Vitamin D deficiency in Mongolian women, the high prevalence of hypertensive pregnancy in Mongolia, and the observational studies linking low 25(OH)D levels with preeclampsia risk, the investigators are conducting a pilot Vitamin D dosing trial to:
* Determine what level of Vitamin D supplementation is needed to secure 25(OH)D levels of at least 20 ng/ml in pregnant Mongolian women
* Generate preliminary data in support of a funding application for a larger trial of Vitamin D supplements to prevent preeclampsia in Mongolia
A double-blind randomized, placebo-controlled trial comparing the impact of 600 IU, 2000 IU, or 4000 IU of Vitamin D3 on third trimester 25(OH)D levels and change from baseline. The Vitamin D will be integrated in a standard prenatal vitamin, which will be taken from 12-16 weeks' gestation and continue throughout pregnancy. Umbilical cord 25(OH)D levels will also be determined. The investigators will generate preliminary data regarding Vitamin D intake and hypertensive disorders, blood pressure, and arterial function measured by tonography. The investigators will independently test blood pressure and proteinuria to identify preeclampsia cases.
The investigators will enroll 360 women who plan to receive their prenatal care and deliver at Zuun Kharaa Hospital in the Selenge province in northern Mongolia. Enrollment will be stratified by season. 120 women will be randomized to each of the three doses of vitamin D (600, 2000, 4000 IU) included in a standard prenatal vitamin.
Calcemia will be monitored two months after randomization and weeks 36-40 of pregnancy. Adverse events of pregnancy will be reported to the Data Safety and Monitoring Board (DSMB) and Institutional Review Board (IRB) per protocol.
Data will be gathered by a Mongolian study coordinator and local clinicians. A DSMB comprised of a U.S. and Mongolian clinicians and statisticians will monitor study data for safety.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
600 IU
Women will receive prenatal vitamins containing 600 IU of Vitamin D.
600 IU Vitamin D3 in prenatal vitamin
Women will receive 600 IU 25(OH)D in prenatal vitamin.
2000 IU
Women will receive prenatal vitamins containing 2000 IU of Vitamin D.
2000 IU Vitamin D3 in prenatal vitamin
Women will receive 2000 IU 25(OH)D in prenatal vitamin.
4000 IU
Women will receive prenatal vitamins containing 4000 IU of Vitamin D.
4000 IU Vitamin D3 in prenatal vitamin
Women will receive 4000 IU 25(OH)D in prenatal vitamin.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
600 IU Vitamin D3 in prenatal vitamin
Women will receive 600 IU 25(OH)D in prenatal vitamin.
2000 IU Vitamin D3 in prenatal vitamin
Women will receive 2000 IU 25(OH)D in prenatal vitamin.
4000 IU Vitamin D3 in prenatal vitamin
Women will receive 4000 IU 25(OH)D in prenatal vitamin.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* 12-16 weeks pregnant
* Receiving prenatal care at Zuun Kharaa Hospital and planning to deliver at Zuun Kharaa Hospital
* Willing not to take any additional vitamin D supplements, other than the study dispensed pills
Exclusion Criteria
* History of kidney stones
* Known sensitivity to multivitamin preparations
* Taking vitamin D supplements containing \>600 IU/day.
18 Years
FEMALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Center for Maternal and Child Health Research, Mongolia
UNKNOWN
Zuun Kharaa Hospital
OTHER
Brigham and Women's Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Janet Rich-Edwards
Director of Developmental Epidemiology
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Janet Rich-Edwards, ScD
Role: PRINCIPAL_INVESTIGATOR
Brigham and Women's Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Zuun Kharaa Hospital
Selenge, Selenge Province, Mongolia
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Enkhmaa D, Tanz L, Ganmaa D, Enkhtur S, Oyun-Erdene B, Stuart J, Chen G, Carr A, Seely EW, Fitzmaurice G, Buyandelger Y, Sarantsetseg B, Gantsetseg G, Rich-Edwards J. Randomized trial of three doses of vitamin D to reduce deficiency in pregnant Mongolian women. EBioMedicine. 2019 Jan;39:510-519. doi: 10.1016/j.ebiom.2018.11.060. Epub 2018 Dec 11.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
14-0591-02
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.